Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 8/20 | 0.71 |
| ▸ | FOLR1 | P15328 | 11/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | SLC46A1 | Q96NT5 | 3/20 | 0.35 |
| ▸ | ATIC | P31939 | 2/20 | 0.35 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996555 | 1.00 | GART (0.71) | GARTFOLR1NOS1FOLR2DHFR | |
| SCHEMBL22967335 | 0.85 | GART (0.59) | GARTFOLR1NOS1ATIC | |
| SCHEMBL10067962 | 0.84 | GART (1.00) | GARTFOLR1FOLR2SLC46A1ATIC | |
| SCHEMBL24846050 | 0.82 | GART (0.57) | GARTFOLR1NOS1DHFRATIC | |
| SCHEMBL7812453 | 0.82 | GART (0.69) | GARTFOLR1NOS1ATIC | |
| SCHEMBL6991867 | 0.82 | GART (0.72) | GARTFOLR1NOS1ATIC | |
| SCHEMBL6993317 | 0.82 | GART (0.72) | GARTFOLR1NOS1ATIC | |
| SCHEMBL8362067 | 0.74 | GART (0.53) | GARTFOLR1NOS1ATIC | |
| SCHEMBL6996839 | 0.73 | GART (0.66) | GARTFOLR1NOS1ATIC | |
| SCHEMBL7825368 | 0.70 | GART (1.00) | GARTFOLR1ATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0846111-B1 | SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| US-5981748-A | Synthesis of optically pure compounds useful as GARFT inhibitors and their intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-09 | — | — | US | disclosed |